Nicholas A.j. Botwood

CIK: 0002066784

Transaction Breakdown

Open Market Buys (P)1 (14.3%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SNDX

Syndax Pharmaceuticals Inc

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

SNDX
Syndax Pharmaceuticals Inc
Jun 12, 2026
Sale(S)
Direct
31.2K shares at avg. $18.14$567K
SNDX
Syndax Pharmaceuticals Inc
Jun 12, 2026
Exercise(M)
Direct
31.2K shares at avg. $13.82$432K
SNDX
Syndax Pharmaceuticals Inc
Jun 11, 2026
Exercise(M)
Direct
22.5K shares at avg. $13.82$311K
SNDX
Syndax Pharmaceuticals Inc
Jun 11, 2026
Sale(S)
Direct
34.3K shares at avg. $18.00$617K
SNDX
Syndax Pharmaceuticals Inc
Feb 4, 2026
Award(A)
Direct
36K shares-
SNDX
Syndax Pharmaceuticals Inc
Feb 4, 2026
Award(A)
Direct
24K shares-
SNDX
Syndax Pharmaceuticals Inc
May 16, 2025
Purchase(P)
Direct
11.8K shares at avg. $8.99$106K

		Type	Shares	Price		Ownership
Jun 12, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	31,235	$18.14	$566,603	Direct
Jun 12, 2026	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	31,235	$13.82	$431,668	Direct
Jun 11, 2026	SNDX Syndax Pharmaceuticals Inc	Exercise(M)	22,515	$13.82	$311,157	Direct
Jun 11, 2026	SNDX Syndax Pharmaceuticals Inc	Sale(S)	34,280	$18.00	$617,040	Direct
Feb 4, 2026	SNDX Syndax Pharmaceuticals Inc	Award(A)	36,000	-	$0	Direct
Feb 4, 2026	SNDX Syndax Pharmaceuticals Inc	Award(A)	24,000	-	$0	Direct
May 16, 2025	SNDX Syndax Pharmaceuticals Inc	Purchase(P)	11,765	$8.99	$105,826	Direct

1-7 of 7 transactions

About Botwood Nicholas A.J.

Botwood Nicholas A.J. (SEC CIK 0002066784) files insider reports with the SEC as Head of R&D, CMO of Syndax Pharmaceuticals Inc (SNDX).

Signal8 holds 4 ownership filings by Botwood Nicholas A.J. (1 Form 3, 3 Form 4), filed between May 16, 2025 and Jun 12, 2026. Those filings report 7 transactions, from May 16, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Botwood Nicholas A.J.'s filings is in NEW YORK, NY.

Recent filings by Botwood Nicholas A.J.

Jun 12, 2026: Open-market sale of SNDX shares (Form 4, code S).
Jun 12, 2026: Option exercise of SNDX shares (Form 4, code M).
Jun 11, 2026: Option exercise of SNDX shares (Form 4, code M).
Jun 11, 2026: Open-market sale of SNDX shares (Form 4, code S).
Feb 4, 2026: Grants or awards of SNDX shares (2 lines, Form 4, code A).

Other insiders filing for Syndax Pharmaceuticals Inc (SNDX)

Podlesak Dennis, Director
Metzger Michael A, Chief Executive Officer
Goldan Keith A., Chief Financial Officer
Jarrett Jennifer, Director
Huber Martin H. Jr., Director
Rizo Aleksandra, Director

How to read Form 4 transaction codes